Seonix Bio

Executive Summary

Seonix Bio, a San Diego-based diagnostics startup founded in 2021, offers SightScore™, a saliva-based polygenic risk score test that predicts genetic predisposition to glaucoma and age-related macular degeneration (AMD). These two eye diseases are leading causes of irreversible blindness worldwide, and early genetic risk assessment could enable proactive monitoring and personalized prevention. The company targets a growing market as consumer genomics and preventive healthcare gain traction, and its direct-to-consumer plus professional distribution model aims to reach both individuals and clinicians. However, Seonix Bio faces challenges: it is a very early-stage company with no disclosed funding, limited public validation data, and operates in a competitive space with established players like 23andMe and specialized ophthalmic genetic tests. Additionally, regulatory pathways for polygenic risk scores are still evolving. Despite these hurdles, the company addresses a clear unmet need—most glaucoma and AMD cases are diagnosed late, and genetic risk awareness could significantly improve outcomes. If Seonix Bio can secure clinical validation, strategic partnerships with eye care providers, and a clear commercialization path, it has the potential to carve out a niche in precision ophthalmology. For now, the company remains a high-risk, unproven venture with a compelling but nascent product.

Upcoming Catalysts (preview)

• Q3 2026Publication of SightScore Clinical Validation Study40% success
• Q4 2026Strategic Partnership with Major Ophthalmology Network25% success
• TBDExpansion of SightScore to Additional Ocular Indications15% success